d cysteine

D-Cysteine 是一种大肠杆菌生长的有力抑制剂，是半胱氨酸的 D 型异构体。它由 D-氨基酸氧化酶介导产生 H2S，是一种对抗小脑共济失调的神经保护剂。 D-半胱氨酸可以抑制由变形链球菌和链球菌血红蛋白形成的两种生物膜的生长和致龋性。

(tert-Butoxycarbonyl)-D-cysteine 是一种有用的有机化合物，可用于生命科学领域的相关研究。其产品编号为 T66872，CAS号为 149270-12-2。

N-Cbz-D-Cysteine (Cbz-D-Cys) (compound 5) 是 β-内酰胺酶 II (β-lactamase II) 的有效抑制剂，其Ki值达到20.1 µM。

N-Boc-S-benzyl-D-cysteine 是一种有用的有机化合物，可用于生命科学领域的相关研究。其产品编号为 T65543，CAS号为 102830-49-9。

D-Ribose-L-cysteine is the antioxidant glutathione precursor.

N-(((9H-Fluoren-9-yl)methoxy)carbonyl)-S-((4-methoxyphenyl)diphenylmethyl)-D-cysteine 是一种用于生命科学领域研究的有用有机化合物，产品编号为 T64441。

D L-Cysteine 是一种有用的有机化合物，可用于生命科学领域的相关研究。其产品编号为 T125019，CAS号为 3374-22-9。

N-Acetyl-D-cysteine 具有抗氧化活性，机制是通过与巯基反应清除ROS。N-Acetyl-D-cysteine 不能进入谷胱甘肽代谢途径。

Penicillamine (Artamine) 是一种 penicillin 的代谢降解产物，是一种螯合剂，可作用于威尔逊氏病。

L-Cysteine S-sulfate (S-Sulfo-L-cysteine) 是有效的 N-methyl-d-aspartate (NMDA) 谷氨酸受体激动剂。L-Cysteine S-sulfate 是胱氨酸裂解酶的底物。

Pyridoxal 5'-phosphate hydrate (PLP) 是内源性代谢产物的一种。

EN219 is a synthetic recruiter of the E3 ubiquitin ligase RNF114.1It binds to cysteine 8 (C8) in the intrinsically disordered region of RNF114 (RNF114-C8; IC50= 470 nM) and inhibits RNF114-induced autoubiquitination and p21 ubiquitination in a cell-free assay when used at a concentration of 50 μM. EN219 (1 μM) also interacts with cysteine residues in the tubulin β1 chain (TUBB1), heat shock protein 60 (Hsp60), also known as Hsp family D member 1 (HspD1), and histone H3.1 (HIST1H3A) in 231MFP human breast cancer cells in a proteomic profiling assay. It has been linked to the bromodomain and extra terminal domain (BET) inhibitor ligand (+)-JQ1 for use as a proteolysis-targeting chimera (PROTAC) to degrade bromodomain-containing protein 4 (BRD4) in 231MFP cells. 1.Luo, M., Spradlin, J.N., Boike, L., et al.Chemoproteomics-enabled discovery of covalent RNF114-based degraders that mimic natural product functionCell Chem. Biol.28(4)559-566(2021)

D,L-Cystathionine dihydrochloride is an intermediate in the synthesis of cysteine, which acts from the isotype of cysteine-β-synthase (CBS) produced by leucine and serine. Derived from cysteine. DL-cysteine contains a cysteine (βC-S) carbon-sulfur bond.

S-(N-Methylsulfinylbutylthiocarbamoyl)-L-cysteine (SFN-Cys) 是一种异硫氰酸酯衍生物及第一类和第二类组蛋白去乙酰化酶（HDAC）抑制剂和抗癌剂硫代硫酸烯醇醚的活性代谢产物。它通过巯基乙酸途径酶从硫代硫酸烯醇醚经DL-硫代硫酸烯醇醚谷胱甘肽和硫代硫酸烯醇醚半胱氨酸甘肽中间体形成。SFN-Cys (20 µM) 通过创伤愈合和腔室分析实验，分别减少了U87MG和U373 MG胶质母细胞瘤细胞的侵袭和迁移。在45 µM的浓度下，它降低了对紫杉醇耐药的A549肺癌细胞（A549/T）中的α-微管蛋白、βIII-微管蛋白、司他敏1和X连锁抑制剂的凋亡（XIAP）的水平，并减少了细胞密度。使用30 µM浓度的SFN-Cys诱导U87MG和U373 MG细胞凋亡和G2/M期细胞周期停滞。

Z-L(D-Val)G-CHN2（即Z-LVG-CHN2）是半胱氨酸蛋白酶抑制剂的异构体，作为一种三肽衍生物，模仿了人体半胱氨酸蛋白酶结合中心的部分结构。它可以抑制HSV，并且能有效阻断SARS-COV-2的3CL pro蛋白酶，从而抑制病毒活性（EC50=190 nM），但对脊髓灰质炎病毒复制无显著作用。

Cathepsin D and E FRET Substrate acetate 是组织蛋白酶 D 和 E 的荧光底物，但不适用于 B、H 或 L。Cathepsin D and E FRET Substrate acetate 可用于组织蛋白酶 D 和 E 研究的机理研究。

Cefminox (Sodium) is a new cephamycin antibiotic possessing a D-amino acid moiety derived from D-cysteine at the C-7B side chain. Cefminox is active against a wide range of bacteria, especially Gram-negative and anaerobic bacteria. Cefminox shows excellent in vivo efficacy (ED50) which is higher than would be expected from its in vitro activity (MIC). Moreover, cefminox possesses more potent activity in suppression of bacterial regrowth than other cephems[1]. Cefminox (Sodium) was the most active beta-lactam, with an MIC at which 50% of isolates are inhibited (MIC50) of 1.0 microg ml and an MIC90 of 16.0 microg ml. Cefminox was especially active against Bacteroides fragilis (MIC90, 2.0 microg ml), Bacteroides thetaiotaomicron (MIC90, 4.0 microg ml), fusobacteria (MIC90, 1.0 microg ml), peptostreptococci (MIC90, 2.0 microg ml), and clostridia, including Clostridium difficile (MIC90, 2.0 microg ml)[2]. The use of a single preoperative dose of cefminox was similar in efficacy to 3 doses of cefoxitin administered every 4 hours, and that the serum and tissue concentrations attained provide adequate antibiotic coverage[3]. Moreover, cefminox as a dual agonist of IP (Prostacyclin receptor) and PPARγ (peroxisome proliferator-activated receptor-gamma) that significantly inhibits PASMC proliferation by up-regulation of PTEN (phosphatase and tensin homolog) and cAMP ( cyclic adenosine monophosphate), suggesting that it has potential for treatment of PAH(pulmonary arterial hypertension)[4].